ArticleInternational journal of clinical and experimental medicine2015
miR-125b suppresses the proliferation of hepatocellular carcinoma cells by targeting Sirtuin7.
Article in International journal of clinical and experimental medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 2 syntheses or guidelines pooled it, 44 citations in OpenAlex.
- Potential role of microRNA‑223‑3p in the tumorigenesis of hepatocellular carcinoma: A comprehensive study based on data mining and bioinformatics.Molecular medicine reports · 2018Pooled it
- Utility of miR‑133a‑3p as a diagnostic indicator for hepatocellular carcinoma: An investigation combined with GEO, TCGA, meta‑analysis and bioinformatics.Molecular medicine reports · 2018Pooled it
- The possible role of sirtuins and MiRNAs in gastrointestinal cancers: special focus on Sirt1.Cancer cell international · 2026Review
- The Protective Role of miR-125b in Hepatocellular Carcinoma: Unraveling Tumor-Suppressive Mechanisms.Current molecular medicine · 2025Review
- The dark side of SIRT7.Molecular and cellular biochemistry · 2024Review
- MiRNAs in Alcohol-Related Liver Diseases and Hepatocellular Carcinoma: A Step toward New Therapeutic Approaches?Cancers · 2023Review
- Baseline Circulating miR-125b Levels Predict a High FIB-4 Index Score in Chronic Hepatitis B Patients after Nucleos(t)ide Analog Treatment.Biomedicines · 2022Article
- A miR-125/Sirtuin-7 pathway drives the pro-calcific potential of myeloid cells in diabetic vascular disease.Diabetologia · 2022Article
- Clinical Significance of MiR-130b and MiR-125b as Biomarkers in Hepatocellular Carcinoma.Asian Pacific journal of cancer prevention : APJCP · 2022Article
- Role of miR-653 and miR-29c in downregulation of CYP1A2 expression in hepatocellular carcinoma.Pharmacological reports : PR · 2022Article
- Essential functions of miR-125b in cancer.Cell proliferation · 2021Review
- De Novo Profiling of Long Non-Coding RNAs Involved in MC-LR-Induced Liver Injury in Whitefish: Discovery and Perspectives.International journal of molecular sciences · 2021Article
- miR-125b prevent the progression of esophageal squamous cell carcinoma through the p38-MAPK signaling pathway.Journal of gastrointestinal oncology · 2020Article
- The possible role of Sirtuins and microRNAs in hepatocellular carcinoma therapy.Cell cycle (Georgetown, Tex.) · 2020Review
- Bone marrow mesenchymal stem cell-secreted exosomes carrying microRNA-125b protect against myocardial ischemia reperfusion injury via targeting SIRT7.Molecular and cellular biochemistry · 2020Article
- Role of microRNA and Long Non-Coding RNA in Hepatocellular Carcinoma.Current pharmaceutical design · 2020Review
- Tumorigenesis, diagnosis, and therapeutic potential of exosomes in liver cancer.Journal of hematology & oncology · 2019Review
- Article
- Development of a Non-Coding-RNA-based EMT/CSC Inhibitory Nanomedicine for In Vivo Treatment and Monitoring of HCC.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2019Article
- Identification of potential miRNA-mRNA regulatory network contributing to pathogenesis of HBV-related HCC.Journal of translational medicine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Previous studies have shown that microRNAs are involved in many human cancers. However, the role of miR-125b in hepatocellular carcinoma (HCC) has not been fully understood. In our study, we detected the expression of miR-125b using Real-time quantitative-polymerase chain reaction (RT-PCR) and found that the expressions of miR-125b were significantly inhibited in HCC tissues and cell lines. The levels of miR-125b were associated with the degree of HCC malignancy. Otherwise, MTT assay showed that the proliferation was significantly decreased after transfection of miR-125b mimics into HepG2 cells; while the proliferation was significantly increased in HepG2 cells transfected with miR-125b inhibitors. Furthermore, TargetScan was conducted to predict the target gene of miR-125b and Sirtuin7 (SIRT7) was chosen to a potential target gene. And then we used luciferase reporter assay and western blot to confirm that SIRT7 is a direct target gene. Western blot indicated that transfection of miR-125b mimics could significantly inhibit the expression of SIRT7 in HepG2 cells, whereas, transfection of miR-125b inhibitor could significantly increase the expression of SIRT7 in HepG2 cells. These results suggest that miR-125b can inhibit the proliferation of HCC by adjusting the expression of SIRT7 and may be a key element of HCC progression.
Indexed as
Identifiers
26770454PMC4694354W2414250949What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.